FOR IMMEDIATE RELEASE - May 21, 2024 - NEW YORK, NY., Hospira, Inc., a Pfizer company ("Pfizer"), is voluntarily recalling the lots listed in the table below of Buprenorphine Hydrochloride Injection CarpujectTM Units and Labetalol Hydrochloride Injection, USP CarpujectTM Units to the User level. The recall was initiated due to the potential for incomplete crimp seals; one customer complaint has been received for one leaking unit. [...]

This is an abstract of the document. To keep reading, click here and get access to the original version.

Attachments

  • Original Link
  • Permalink

Disclaimer

Pfizer Inc. published this content on 21 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 May 2024 20:57:21 UTC.